{"classes":[{"categories":[{"measurements":[{"comment":"Not enough participants reached the threshold to support estimating the upper range.","groupId":"OG000","lowerLimit":"1.0","upperLimit":"NA","value":"3.0"},{"comment":"Not enough participants reached the threshold to estimate the values.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"147"},{"groupId":"OG001","value":"142"}],"units":"Participants"}],"description":"The Kaplan Meier estimate of median number of days (number of days at which 50% of participants reached the threshold, accounting for censored values) in each treatment arm to collect the target number of cells (≥5\\*10\\^6 CD34+ cells/kg) for transplantation. Central laboratory values were used.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of plerixafor. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of plerixafor for a maximum of 4 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"G-CSF + Plerixafor"},{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of placebo. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of placebo for a maximum of 4 aphereses or until ≥ 5\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"G-CSF Plus Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-Treat Population.","reportingStatus":"POSTED","timeFrame":"up to Day 8","title":"Median Number of Days of Apheresis Required to Achieve >=5*10^6 CD34+ Cells/kg","type":"SECONDARY","unitOfMeasure":"Days"}